WO2005032278A1 - SOLUBILIZED CoQ-10 - Google Patents
SOLUBILIZED CoQ-10 Download PDFInfo
- Publication number
- WO2005032278A1 WO2005032278A1 PCT/US2004/031775 US2004031775W WO2005032278A1 WO 2005032278 A1 WO2005032278 A1 WO 2005032278A1 US 2004031775 W US2004031775 W US 2004031775W WO 2005032278 A1 WO2005032278 A1 WO 2005032278A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coenzyme
- analog
- composition
- coq
- solubilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- CoQ-10 (coenzyme Q10) is a fat-soluble quinone that is structurally similar to vitamin K and commonly known as ubiquinone. CoQ-10 is found in most living organisms, and is essential for the production of cellular energy. CoQ-10 (2,3 dimethyl-5 methyl-6-decaprenyl benzoq ⁇ inone) is an endogenous antioxidant found in small amounts in meats and seafood. Although CoQ-10 is found in all human cells, the highest concentrations of CoQ-10 occur in the heart, liver, kidneys, and pancreas. It is found naturally in the organs of many mammalian species.
- CoQ-10 can be synthesized in the body or it can be derived from dietary sources. Situations may arise, however, when the need for CoQ-10 surpasses the body's ability to synthesize it. CoQ-10 can be absorbed by oral supplementation as evidenced by significant increases in serum CoQ-10 levels after supplementation.
- CoQ-10 is an important nutrient because it lies within the membrane of a cell organelle called the mitochondria. Mitochondria are known as the "power house" of the cell because of their ability to produce cellular energy, o r A TP, b y s huttling p rotons d erived from nutrient b reakdown through the process of aerobic (oxygen) metabolism.
- CoQ-10 also has a secondary role as an antioxidant.
- CoQ-10 due to the involvement in ATP synthesis, affects the function of almost all cells in the body, making it essential for the health of all human tissues and organs. CoQ-10 particularly effects the cells that are the most metabolically active: heart, immune system, gingiva, and gastric mucosa [006]
- Several clinical trials have shown CoQ-10 to be effective in supporting blood pressure and cholesterol levels.
- CoQ-10 has also been s hown t o i mprove c ardiovascular h ealth.
- CoQ-10 supplementation is vital to an individual's well being.
- CoQ-10 is sparingly soluble in most hydrophilic solvents such as water. Therefore, CoQ-10 is often administered in a powdered form, as in a tablet or as a suspension. However, delivery of CoQ-10 by these methods limits the bioavailability of the material to the individual.
- BRIEF SUMMARY OF THE INVENTION [009] The present invention pertains to the surprising discovery that ubiquinone (CoQ-10) and related analogs thereof can be readily dissolved in varying concentrations in monoterpenes.
- CoQ-10 liquid delivery methods could solubilize only up to about 5% by weight of the CoQ-10 in the "solvent".
- Typical solvents included various oils or the CoQ-10 was held in suspension.
- the present invention provides the ability to solubilize CoQ-10 in monoterpenes in concentrations of up to about 60% (weight to weight) without the need to aggressively heat the solution or with gentle warming.
- the solubilization of the CoQ-10 with monoterpenes can be accomplished at ambient temperatures.
- the present invention pertains to compositions that include coenzyme Q-10 or an analog thereof with a sufficient quantity of a monoterpene that is suitable to solubilize said coenzyme Q-10 and a pharmaceutically acceptable carrier.
- a monoterpene that is suitable to solubilize said coenzyme Q-10 and a pharmaceutically acceptable carrier.
- about 30 to about 45% of the CoQ-10 (by weight) is solubilized in the monoterpene.
- the monoterpene is limonene.
- the compositions of the invention are useful as dietary supplements or as nutriceuticals.
- compositions of the invention are included in a soft gelatin (soft gel) capsule.
- the soft gelatin capsule includes at least
- Typical monoterpenes include, for example, perillyl alcohol, perillic acid, cis-dihydroperillic acid, trans-dihydroperillic acid, methyl esters of perillic acid, methyl esters of dihydroperillic acid, limonene-2-diol, uroterpenol, and combinations thereof.
- the present invention pertains to methods for delivery of an effective amount of bioavailable CoQ-10 to an individual.
- the method includes providing CoQ-10 solubilized in a monoterpene, such that an effective amount of CoQ-10 is provided to the individual.
- the present invention also includes packaged formulations of the invention that include a monoterpene as a solvent for the CoQ-10 and instructions for use of the tablet, capsule, elixir, etc.
- the present invention provides solubilized coenzyme
- compositions that include coenzyme Q-10 or an analog thereof, a sufficient quantity of a monoterpene suitable to solubilize said coenzyme Q-10 or analog thereof, and an acceptable carrier.
- the compositions provide a percentage of coenzyme Q-10 dosage that is absorbed by an individual of between about 5 percent and about 12 percent of said coenzyme Q-10 or analog thereof that is administered.
- the ranges of absorbed coenzyme Q-10 are from about 5 percent to about 12 percent, from about 6 percent to about 10 percent, and from about 6.5 percent to about 9.5 percent, based on the dosage of coenzyme Q-10 or analog thereof taken.
- the present invention provides solubilized coenzyme Q-10 compositions that include coenzyme Q-10 or an analog thereof, a sufficient quantity of a monoterpene suitable to solubilize said coenzyme Q-10 or analog thereof, and an acceptable carrier.
- the compositions provide a bioavailable steady state plasma level of coenzyme Q-10 or an analog thereof of between about 2.5 ⁇ g/ml to about 3.5 ⁇ g/ml.
- Suitable ranges of steady state plasma levels of coenzyme Q-10 or analog thereof are from about 2.5 ⁇ g/ml to about 3.5 ⁇ g/ml, from about 2.75 ⁇ g/ml to about 3.25 ⁇ g/ml and from about 2.75 ⁇ g/ml to about 3.0 ⁇ g/ml, based on the dosage of coenzyme Q-10 or analog thereof taken.
- the present invention provides compositions that include solubihzed coenzyme Q-10 or an analog thereof, a sufficient quantity of a monoterpene suitable to solubilize said coenzyme Q-10 or analog thereof, and an acceptable carrier.
- the compositions provide a peak plasma level of coenzyme Q-10 or analog thereof of between about 2.1 ⁇ g/ml to I about 3.0 ⁇ g/ml. Suitable ranges of peak plasma levels of coenzyme Q-10 or analog thereof are from about 2.1 ⁇ g/ml to about 3.0 ⁇ g/ml, from about 2.2 ⁇ g/ml to about 2.8 ⁇ g/ml and from about 2.2 ⁇ g/ml to about 2.5 ⁇ g/ml.
- the present invention pertains to methods for delivery of an effective amount of bioavailable CoQ-10 to an individual.
- the methods include providing CoQ-10 solubilized in a monoterpene, such that an effective amount of CoQ-10 is provided to the individual so that the dosage absorbed, the steady state plasma levels of coenzyme Q-10, or the peak plasma levels of coenzyme Q-10 are sustained.
- the present invention also includes packaged formulations of the invention that include a monoterpene as a solvent for the CoQ-10 and instructions for use of the tablet, capsule, elixir, etc. so that the dosage absorbed, the steady state plasma levels of coenzyme Q-10, or the peak plasma levels of coenzyme Q-10 are sustained.
- Figure 2 shows individual daily dose (60 mg/day) steady state plasma coenzyme Q-10 bioavailability curves for the solubilized coenzyme Q-10;
- Figure 3 provides a graphical representation of single dose peak absorption curves for the solubilized coenzyme Q-10 (60 mg) (upper line, ⁇ )(Example 5) formulation and Example 6 (30 mg) (lower line, ⁇ ).
- the Cmax for both formulations occurred at 6 hours.
- the change in plasma coenzyme Q-10 at Cmax was significantly greater for the solubilized coenzyme Q-10 by a three fold factor.
- Figure 4 is a graphical representation of the steady state bioavailability curves for the solubilized coenzyme Q-10 (upper line, ⁇ )(Example 5) and Example 6 (lower line, ⁇ ) at a daily dose of 60 mg/day. Plasma levels at 7,
- the present invention pertains to the surprising discovery that ubiquinone (CoQ-10) can be readily dissolved in varying concentrations in monoterpenes.
- CoQ-10 is found in most living organisms, and is essential for the production of cellular energy.
- Ubiquinone is a naturally occurring hydrogen carrier in the respiratory chain (coenzyme Q) and structurally, it is a 2,3- dimethoxy-5-methyl-l,4-benzoquinone with a multiprenyl side chain, the number of isoprene units varying depending upon the organism from which it is derived.
- CoQ-10 analogs include reduced and semi-reduced CoQ-10 and ubiquinone derivatives described, for example, in WO 8803015, the teachings of which are incorporated herein by reference.
- CoQ-10 liquid delivery methods could solubilize only up at most about 10% by weight of the CoQ-10 in the solvent.
- Typical solvents included oils or the CoQ-10 was held in an aqueous suspension.
- the CoQ-10 was provided as a solid in a tablet or powder.
- the present invention provides the ability to solubilize CoQ-10 and analogs thereof in monoterpenes, as defined herein, in concentrations of up to about 60% (weight to weight) without the need to heat the solution, hi one aspect, the monoterpene solubilizes CoQ-10 from about 0.1 percent by weight to about 45 percent by weight.
- the solubilization of the CoQ-10 and analogs thereof with monoterpenes can be accomplished at ambient temperatures, h one aspect, from about 5 to about 50 percent (weight CoQ-10/weight solvent) CoQ-10 can be solubilized in a monoterpene. In another aspect, from about 15 to about 40 percent w/w can be solubilized and in still another aspect, from about 20 to about 35 percent w/w CoQ-10 can be solubilized in a monoterpene. [028]
- the phrase "sufficient quantity of a monoterpene suitable to solubilize coenzyme Q-10" is therefore intended to mean that that amount of a monoterpene that will dissolve CoQ-10 under a given set of conditions, generally, those at ambient temperature.
- a particular advantage in using monoterpenes is that the CoQ-10 or analog thereof does not have to be heated to dissolve into solution. This is important so that the CoQ-10 or analog thereof does not degrade upon dissolution.
- the term "monoterpene” as used herein, refers to a compound having a 10-carbon skeleton with non-linear branches. A monoterpene refers to a compound with two isoprene units connected in a head-to-end manner.
- the term “monoterpene” is also intended to include “monoterpenoid”, which refers to a monoterpene-like substance and may be used loosely herem to refer collectively to monoterpenoid derivatives as well as monoterpenoid analogs.
- Monoterpenoids can therefore include monoterpenes, alcohols, ketones, aldehydes, ethers, acids, hydrocarbons without an oxygen functional group, and so forth.
- phenolic compounds such as eugenol, thymol and carvacrol
- these compounds are not technically "monoterpenoids” (or “monoterpenes”) because they are not synthesized by the same isoprene biosynthesis pathway, but rather by production of phenols from tyrosine.
- common practice will be followed herein.
- Suitable examples of monoterpenes include, but are not limited to, limonene, pinene, cintronellol, terpinene, nerol, menthane, carveol, S-linalool, safjrol, cinnamic acid, apiol, geraniol, thymol, citral, carvone, camphor, etc. and derivatives thereof.
- terpenes including terpenes of the invention, see Kirk-Othrner Encyclopedia of Chemical Technology, Mark, et al, eds., 22:709-762 3d Ed (1983), the teachings of which are incorporated herein in their entirety.
- suitable limonene derivatives include perillyl alcohol, perillic acid, cis-dihydroperillic acid, frans-dihydroperillic acid, methyl esters of perillic acid, methyl esters of dihydroperillic acid, limonene-2-diol, uroterpenol, and combinations thereof.
- CoQ-10 and analogs thereof can be accomplished by many methods known in the art.
- the solubilized CoQ-10 or analog thereof can be formulated in a suspension, an emulsion, an elixir, a solution, a caplet that harbors the liquid, or in a soft gelatin capsule.
- the formulation will include an acceptable carrier, such as an oil, or other suspending agent.
- Suitable carriers include but are not limited to, for example, fatty acids, esters and salts thereof, that can be derived from any source, including, without limitation, natural or synthetic oils, fats, waxes or combinations thereof. Moreover, the fatty acids can be derived, without limitation, from non- hydrogenated oils, partially hydrogenated oils, fully hydrogenated oils or combinations thereof.
- Non-limiting exemplary sources of fatty acids include seed oil, fish or marine oil, canola oil, vegetable oil, safflower oil, sunflower oil, nasturtium seed oil, mustard seed oil, olive oil, sesame oil, soybean oil, corn oil, peanut oil, cottonseed oil, rice bran oil, babassu nut oil, palm oil, low erucic rapeseed oil, palm kernel oil, lupin oil, coconut oil, flaxseed oil, evening primrose oil, jojoba, tallow, beef tallow, butter, chicken fat, lard, dairy butterfat, shea butter or combinations thereof.
- Specific non-limiting exemplary fish or marine oil sources include shellfish oil, tuna oil, mackerel oil, salmon oil, menhaden, anchovy, herring, trout, sardines or combinations thereof.
- the source of the fatty acids is fish or marine oil (DHA or EPA), soybean oil or flaxseed oil.
- beeswax can be used as a suitable carrier, as well as suspending agents such as silica (silicon dioxide).
- the formulations of the invention are considered dietary supplements useful to the increase the amounts of CoQ-10 and analogs thereof in the individuals in need thereof.
- the formulations of the invention are also considered to be nutraceuticals.
- the term "nutraceutical” is recognized in the art and is intended to describe specific chemical compounds found in foods that may prevent disease. CoQ-10 or an analog thereof are such compounds.
- the formulations of the invention can further include various ingredients to help stabilize, or help promote the bioavailability of the C oQ-10 and analogs thereof, or serve as additional nutrients to an individual's diet.
- Suitable additives can include vitamins and biologically-acceptable minerals.
- vitamins include vitamin A, B vitamins, vitamin C, vitamin D, vitamin E, vitamin K and folic acid.
- Non-limiting examples of minerals include iron, calcium, magnesium, potassium, copper, chromium, zinc, molybdenum, iodine, boron, selenium, manganese, derivatives thereof or combinations thereof.
- Non-limiting exemplary B vitamins include, without limitation, thiamine, niacinamide, pyridoxine, riboflavin, cyanocobalamin, biotin, pantothenic acid or combinations thereof.
- Vitamin(s), if present, are present in the composition of the invention in an amount ranging from about 5 mg to about 500 mg. More particularly, the vitamin(s) is present in an amount ranging from about 10 mg to about 400 mg. Even more specifically, the vitamin(s) is present from about 250 mg to about 400 mg. Most specifically, the vitamin(s) is present in an amount ranging from about 10 mg to about 50 mg.
- B vitamins are in usually incorporated in the range of about 1 milligram to about 10 milligrams, i.e., from about 3 micrograms to about 50 micrograms of B12.
- Folic acid for example, is generally incorporated in a range of about 50 to about 400 micrograms, biotin is generally incorporated in a range of about 25 to about 700 micrograms and cyanocobalamin is incorporated in a range of about 3 micrograms to about 50 micrograms.
- Mineral(s) if present, are present in the composition of the invention in an amount ranging from about 25 mg to about 1000 mg. More particularly, the mineral(s) are present in the composition ranging from about 25 mg to about 500 mg. Even more particularly, the mineral(s) are present in the composition in an amount ranging from about 100 mg to about 600 mg.
- Various additives can be incorporated into the present compositions.
- Optional additives of the present composition include, without limitation, phospholipids, L -carmtine, starches, sugars, fats, antioxidants, amino acids, proteins, flavorings, coloring agents, hydrolyzed starch(es) and derivatives thereof or combinations thereof.
- phospholipid is recognized in the art, and refers to phosphatidyl glycerol, phosphatidyl inositol, phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, as well as phosphatidic acids, ceramides, cerebrosides, sphingomyelins and cardiolipins.
- L-carnitine is recognized in the art and facilitates transport of materials through the mitochondrial membrane.
- L-carnitine is an essential fatty acid metabolism cofactor that helps to move fatty acids to the mitochondria from the cytoplasm. This is an important factor as this is where CoQ-10 uptake occurs.
- L -carnitine is included in soft gel formulations in combination with CoQ-10 or an analog thereof. Suitable ratios of L-carnitine and CoQ-10 are known in the art and include those described in US Patent No. 4,599,232, issued to Sigma Tau Industrie Faramaceutiche Riunite S.p.A. on July 8, 1986, the teachings of which are incorporated herein in their entirety. In particular, combinations of limonene, CoQ-10 and L-carnitine in soft gel formulations are of importance.
- the present invention provides the advantage of solvatmg large amounts (relative to that of current state of the art) of
- CoQ-10 in limonene in a soft gel capsule along with an additive, such as L- carnitine.
- antioxidant refers to synthetic or natural substances that prevent or delay the oxidative deterioration of a compound.
- exemplary antioxidants include tocopherols, flavonoids, catechins, superoxide dismutase, lecithin, gamma oryzanol; vitamins, such as vitamins A, C (ascorbic acid) and E and beta-carotene; natural components such as camosol, carnosic acid and rosmanol found in rosemary and hawthorn extract, proanthocyanidins such as those found in grapeseed or pine bark extract, and green tea extract.
- flavonoid as used herein is recognized in the art and is intended to include those plant pigments found in many foods that are thought to help protect the body from cancer. These include, for example, epi-gallo catechin gallate (EGCG), epi-gallo catechin (EGC) and epi-catechin (EC).
- EGCG epi-gallo catechin gallate
- ECC epi-gallo catechin
- EC epi-catechin
- isolated CoQ-10 and analogs thereof is intended to mean that the coenzyme Q-10 is solvated by the lipophilic materials incorporated into the soft gel capsule.
- Typical capsules that contain CoQ-10 or an analog thereof include the coenzyme or analog as a dry powder or as a suspension of crystals.
- the powder or crystallinity of the coenzyme does not facilitate absorption by the cells.
- the present invention overcomes this disadvantage by providing formulations wherein the coenzyme is not in a powdered or crystalline form. Microscopic evaluations of the lipophilic formulations do not show crystals of the coenzyme. Consequently, it is believed that the solvated coenzyme can more easily pass into cells. This is highly advantageous in delivering increased amounts of the coenzyme into an individual's physiological make up.
- any dosage form, and combinations thereof, are contemplated by the present invention.
- dosage forms include, without limitation, chewable tablets, elixirs, liquids, solutions, suspensions, emulsions, capsules, soft gelatin capsules, hard gelatin capsules, caplets, lozenges, chewable lozenges, suppositories, creams, topicals, ingestibles, injectables, infusions, health bars, confections, animal feeds, cereals, cereal coatings, and combinations thereof.
- the preparation of the above dosage forms are well known to persons of ordinary skill in the art.
- h ealth b ars c an b e p repared, w ithout 1 imitation, b y mixing the formulation plus excipients (e.g., binders, fillers, flavors, colors, etc.) to a plastic mass consistency.
- excipients e.g., binders, fillers, flavors, colors, etc.
- the mass is then either extended or molded to form "candy bar" shapes that are then dried or allowed to solidify to form the final product.
- Soft gel or soft gelatin capsules can be prepared, for example, without limitation, by dispersing the formulation in an appropriate vehicle (e.g. rice bran oil, monoterpene and/or beeswax) to form a high viscosity mixture. This mixture is then encapsulated with a gelatin based film using technology and machinery known to those in the soft gel industry. The industrial units so formed are then dried to constant weight. Typically, the weight of the capsule is between about 100 to about 2500 milligrams and in particular weigh between about 1500 and about 1900 milligrams, and more specifically can weigh between about 1500 and about 2000 milligrams.
- an appropriate vehicle e.g. rice bran oil, monoterpene and/or beeswax
- This mixture is then encapsulated with a gelatin based film using technology and machinery known to those in the soft gel industry.
- the industrial units so formed are then dried to constant weight.
- the weight of the capsule is between about 100 to about 2500 milligrams and in particular weigh between about 1500
- the shell when preparing soft gelatin shells, can include between about 20 to 70 percent gelatin, generally a plasticizer and about 5 to about 60% by weight sorbitol.
- the filling of the soft gelatin capsule is liquid (principally limonene, in combination with rice bran oil and/or beeswax if desired) and can include, apart form the antioxidant actives, a hydrophilic matrix.
- the hydrophilic matrix if present, is a polyethylene glycol having an average molecular weight of from about 200 to 1000. Further ingredients are optionally thickening agents.
- the hydrophilic matrix includes polyethylene glycol having an average molecular weight of from about 200 to 1000, 5 to 15%) glycerol, and 5 to 15% by weight of water.
- the polyethylene glycol can also be mixed with propylene glycol and/or propylene carbonate.
- the soft gel capsule is prepared from gelatin, glycerine, water and various additives. Typically, the percentage (by weight) of the gelatin is between about 30 and about 50 weight percent, in particular between about 35 and about weight percent and more specifically about
- the formulation includes between about 15 and about 25 weight percent glycerine, more particularly between about 17 and about 23 weight percent and more specifically about 20 weight percent glycerine.
- the remaining portion of the capsule is typically water. The amount varies from between about 25 weigh percent and about 40 weight percent, more particularly between about 30 and about 35 weight percent, and more specifically about 35 weight percent.
- the remainder of the capsule can vary, generally, between about 2 and about 10 weight percent composed of a flavoring agent(s), sugar, coloring agent(s), etc. or combination thereof.
- the water content of the final capsule is often between about 5 and about 10 weight percent, more particularly 7 and about 12 weight percent, and more specifically between about 9 and about 10 weight percent.
- the manufacturing it is contemplated that standard soft shell gelatin capsule manufacturing techniques can be used to prepare the soft-shell product.
- useful manufacturing techniques are the plate process, the rotary die process pioneered by R. P. Scherer, the process using the Norton capsule machine, and the Accogel machine and process developed by Lederle. Each of these processes are mature technologies and are all widely available to any one wishing to prepare soft gelatin capsules.
- the total weight is between about 250 milligrams and about 2.5 gram in weight, e.g., 400-750 milligrams.
- the total weight of additives is between about 80 milligrams and about 2000 milligrams, alternatively, between about 100 milligrams and about 1500 milligrams, and in particular between about 120 milligrams and about 1200 milligrams.
- a soft gel capsule can be prepared by mixing a 35% solution of CoQ-10 and limonene (w/w) (e.g., 104 milligrams of CoQ-10 in 193.14 milligrams of limonene) with between about 0.01 grams and about 0.4 grams (e.g., 0.1 grams) tocopherol, between about 200 grams and about 250 grams (e.g., 225 grams) rice bran oil and between about 0.01 grams and about 0.5 grams betacarotene (e.g. about 0.02 grams). The mixture is then combined with encapsulated within a gelatin capsule as described above.
- limonene w/w
- tocopherol between about 200 grams and about 250 grams (e.g., 225 grams) rice bran oil
- betacarotene e.g. about 0.02 grams
- the present invention also provides packaged formulations of a monoterpene with CoQ-10 and instructions for use of the tablet, capsule, elixir, etc.
- the packaged formulation in whatever form, is administered to an individual in need thereof that requires and increase in the amount of CoQ-10 in the individual's diet.
- the dosage requirements is between about 1 to about 4 dosages a day.
- CoQ-10 has been implicated in various biochemical pathways and is suitable for the treatment of cardiovascular conditions, such as those associated with, for example, statin drugs that effect the body's ability to produce CoQ-10 naturally.
- CoQ-10 has also been implicated in various periodontal diseases.
- CoQ-10 has been implicated in mitochondrial related diseases and disorders, such as the inability to product acetyl coenzyme A, neurological disorders, for example, such as Parkinson's disease and, Prater- illey syndrome.
- mitochondrial related diseases and disorders such as the inability to product acetyl coenzyme A
- neurological disorders for example, such as Parkinson's disease and, Prater- illey syndrome.
- the following examples are intended to be illustrative only and should not be considered limiting. [061] Examples
- Formulations of CoQ-10 can be prepared in the following ratios by mixing the components together and then placing into a soft gel capsule.
- Example 2 CoQ-10 104.09 mg 104.09 mg Mixed Tocopherols 269.03 mg 269.03 mg (372 IU/g) Rice Bran Oil 176.02 mg Natural Beta Carotene 10.05 mg 10.05 mg (20% by weight) Yellow Beeswax 20.0 mg D-limonene 196.02 mg TToottaall wweeiigghhtt 558800 mmgg 580 mg
- Example 2 demonstrates that the use of limonene solubilizes CoQ-
- Examples 1 and 2 can be incorporated into soft gel capsules by standard methods known in the art.
- Example 3 CoQ-10 17.95 g 17.95 g EPAX 2050TG 48.77 g 45.49 g DD--LLiimmoonneennee 3355..7700 gg 35.70 g 5-67 Tocopherol 0.86 g (1000 IU/g) [064]
- Examples 3 and 4 demonstrate that CoQ-10 can be solubilized in scalable quantities. Additives, such as EPAX 2050 TG (an ⁇ -3 oil; 20% EPA/50% DHA as triglycerides, remainder fatty acid triglycerides; Pronova Biocare) and focopherols (5 ⁇ 67 Tocopherol; BD Industries) can easily be incorporated into such limonene containing formulations.
- the resultant mixtures contained approximately 100 mg of CoQ-10 per soft gel capsule. Preparation of the soft gel capsules was accomplished by methods well known in the art.
- Example 6 CoQ-10 (98%) 62,45 mg 62.45 mg Vitamin E mixed tocopherols 69.19 mg 161.3. mg (700 mg/g) D-Limonene 118.1 mg none Soybean oil 30.26 mg none 5-67 Tocopherol 60.0 mg none yellow beeswax none 15.0 mg Rice bran oil none 188.71 mg Natural beta Carotene none 7.54 mg mg/capsule mg/capsule
- Examples 5 and 6 provide a comparison between soft gel capsules prepared with D-limonene and without D-limonene and enzyme CoQ-10. Examples 5 and 6 will be referred to throughout the following paragraphs to show efficacy in delivery with the use of the monoterpene, D-limonene.
- the solubilized CoQ 10 formulation was a soft gel capsule that contained 60 mg CoQ 10 , 118.1 mg limonene, 30.26 mg soybean oil and vitamin E as described in Example 5.
- the non-solubilized formulation was a soft gel capsule that contained 60 mg CoQ 10 , 188.71 mg rice bran oil, 161.3 mg vitamin E (and additional additives) as described in Example 6.
- Group mean control plasma CoQ 10 level (0.88 ⁇ 0.13 ⁇ g/ml) was in the normal range. Tmax after ingestion of a single 60 mg capsule was in six (6) hours and the mean peak plasma level (Cmax) was 2.28 ⁇ 0.14 ⁇ g/ml. The amount of solubilized CoQ 10 absorbed at Cmax was 4,765.51 ⁇ 825.39 ⁇ g or 7.96 ⁇ 1.38 % of the ingested dose. With daily dosing the plasma solubilized CoQ 10 level increased to a mean plateau level of 2.68 ⁇ 0.15 ⁇ g/ml in 14 days and remained fairly constant thereafter. The 28-day plasma level was 2.75 ⁇ 0.22 ⁇ g/ml.
- the solubilized CoQ 10 bioavailability in plasma was 6,498.90 ⁇ l,634.76 ⁇ g, and the area under the plasma time base curve was 42.27 ⁇ 2.29 ⁇ g/ ml* day. These data demonstrate that the solubilized CoQ 10 formulation was absorbed significantly (pO.OOl). The p eak absorption of 7.96% o f the ingested dose and the steady state bioavailability after 28 days was significantly (pO.Ol) greater than that found in Example 6.
- the solubilized CoQio formulation (Example 5) absorption is greater than that of most softgel CoQ 10 products in which CoQ 10 crystals are suspended in a lipid b ase and those products that provide only a dried p owder composition.
- CoQ 10 Coenzyme Q 10
- CoQ 10 Coenzyme Q 10
- the absorption of CoQ 10 is not the same for all CoQ 10 products found in the market place. In general dry powder delivery systems have 0.5 to 2% peak absorption.
- Dry powder CoQ 10 in a lipid base that is incorporated into soft gelatin capsules has better peak absorption (2.0-3.0%). This appears to be dependant on the number and size of the CoQio crystals in the product.
- the following data relate to peak absorption characteristics of a single 60 mg dose and the steady state bioavailability of a daily 60mg dose for the solubilized COQ ⁇ O softgel formulation. Both studies were conducted on the same five (5) normal volunteer subjects. Peak absorption and steady state bioavailability characteristics were compared to that of Example 6 which was collected using a similar study design but different volunteers.
- EDTA EDTA to prevent clotting.
- the samples were cooled in ice water and then centrifuged to separate the plasma from the formed elements.
- the plasma was pipetted into a sealable transfer container, labeled according to volunteer identification and hour of collection and frozen at -20° centigrade. All plasma samples were shipped overnight in dry ice to an independent laboratory for CoQ 10 analysis. T he m ethod u sed w as t hat a s d escribed i n M orita & F olkers ( supra) hexane extraction and HPLC detection.
- the amount of CoQ 10 absorbed at Cmax was 4,769.51 ⁇ 825.39 ⁇ g. When compared to the ingested dose (60,000 ⁇ g), the percent of the dose absorbed at Cmax was 7.95 ⁇ 1.38%. In the first two hours after Cmax an average of 2196.14 ⁇ 523.83 ⁇ g was distributed out o f the b lood and into the body cells. The amount was 46.46 ⁇ 9.85 %> of that absorbed at Cmax. II: Steady State Plasma CoQ 10 Bioavailability
- Example 6 showed that Example 6 had many small crystals of CoQ 10 , whereas the solubilized CoQ 10 (Example 5) showed no crystals, and appeared to be a homogenous distribution of CoQ 10 molecules in solution.
- the study determined the peak single dose (60mg) absorption characteristics and the steady state plasma CoQ 10 bioavailability in response to a constant daily dose of 60mg/day for 28 days of solubilized CoQ 10 .
- Example 6 at a dose of 30 mg is significantly (p ⁇ 0.01) less absorbed than 60 mg of solubilized CoQ 10 formulation.
- the steady state bioavailability of Example 6 is also significantly less than that of solubilized CoQ 10 formulation as shown in Figure 4.
- Example 6 resulted in a group mean steady state plasma CoQ 10 level of 2.26 ⁇ 0.74 ⁇ g/ml. This is significantly (p ⁇ O.01) less than the 2.75 ⁇ 0.22 ⁇ g/ml measured for the solubilized CoQ 10 formulation using the same 60 mg/day dose.
- Example 5 has better absorption than Example 6 may be explained by the physical characteristics of the two formulations.
- Example 6 and the solubilized CoQ 10 formulations were made by the same soft gel encapsulating process. T he i ngredients i n t he t wo formulations w ere d ifferent r elative t o t he lipid carrier molecules (Rice bran oil in Example 6 and Soybean oil and D- Limonene oil in the solubilized CoQ 10 formulation (Example 5)). On examination of the two formulations, the contents of both were an oily m atrix.
- Example 6 was reddish brown in color due to the beta-carotene.
- the solubilized CoQ 10 formulation was dark brown in color. Upon microscopic examination Example 6 was found to have small crystals, whereas the solubilized
- CoQ 10 was devoid of crystals. It is postulated that the solubilized CoQ 10 formulation consists of a larger fraction of single CoQio molecules and exerts a greater osmotic concentration of CoQ 10 outside the intestinal cells, thus a greater driving force for the facilitated diffusion process for CoQ 10 absorption.
- the CoQio crystal has a melting point 10° centigrade above body temperature (37°C) and completely melt to single molecules at 65° centigrade, it is believed that the lower absorption of Example 6 is due to the larger proportion of CoQ 10 crystals in solution and the physiological fact that the body cannot absorb a crystal. Only single molecules in water or lipid solution can be absorbed across the intestinal mucosal membrane or transported across any epithelial cell membrane.
- the solubilized CoQio formulation peak absorption kinetics and steady state bioavailability is significantly greater than that of Example 6.
- the 7.95%o absorption of the ingested dose makes this a superior composition to provide increased amounts of CoQ 10 to a subject in need thereof.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04785186A EP1670325A1 (en) | 2003-09-29 | 2004-09-29 | SOLUBILIZED CoQ-10 |
JP2006528309A JP4758898B2 (en) | 2003-09-29 | 2004-09-29 | Solubilized CoQ-10 |
AU2004277951A AU2004277951B2 (en) | 2003-09-29 | 2004-09-29 | Solubilized CoQ-10 |
IL174624A IL174624A (en) | 2003-09-29 | 2006-03-29 | Solubilized coenzyme q-10 composition and a packaged nutraceutical formulation containing it |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/674,268 | 2003-09-29 | ||
US10/674,268 US8124072B2 (en) | 2003-09-29 | 2003-09-29 | Solubilized CoQ-10 |
US10/953,328 | 2004-09-29 | ||
US10/953,328 US8105583B2 (en) | 2003-09-29 | 2004-09-29 | Solubilized CoQ-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005032278A1 true WO2005032278A1 (en) | 2005-04-14 |
Family
ID=34426371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/031775 WO2005032278A1 (en) | 2003-09-29 | 2004-09-29 | SOLUBILIZED CoQ-10 |
Country Status (4)
Country | Link |
---|---|
US (6) | US8105583B2 (en) |
EP (1) | EP1670325A1 (en) |
AU (1) | AU2004277951B2 (en) |
WO (1) | WO2005032278A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007297395A (en) * | 2006-05-05 | 2007-11-15 | Softgel Formulators Inc | Highly absorbable coenzyme q10 composition and method for producing the same |
WO2007143651A2 (en) * | 2006-06-05 | 2007-12-13 | Soft Gel Technologies, Inc. | Chewable co-enzyme q-10 capsule |
WO2008113066A2 (en) * | 2007-03-15 | 2008-09-18 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic compositions |
US7713523B2 (en) | 2003-09-29 | 2010-05-11 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 and carnitine |
US8865032B2 (en) | 2003-09-29 | 2014-10-21 | Soft Gel Technologies, Inc. | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene |
US8932585B2 (en) | 2003-09-29 | 2015-01-13 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6616942B1 (en) * | 1999-03-29 | 2003-09-09 | Soft Gel Technologies, Inc. | Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing |
US6623734B2 (en) * | 2000-06-22 | 2003-09-23 | Soft Gel Technologies, Inc. | Super absorption coenzyme Q10 |
US20040161436A1 (en) * | 2003-02-13 | 2004-08-19 | Hull Barbara A. | Skin treatment composition and method |
US20080089877A1 (en) * | 2003-08-14 | 2008-04-17 | Udell Ronald G | Super Absorption Coenzyme Q10 |
US8147825B2 (en) | 2004-01-22 | 2012-04-03 | University Of Miami | Topical co-enzyme Q10 formulations and methods of use |
US8252326B2 (en) * | 2005-06-01 | 2012-08-28 | Catalent Australia Pty Ltd. | Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10 |
US20070184040A1 (en) * | 2006-02-06 | 2007-08-09 | Clouatre Dallas L | Compositions for delivery of coenzyme Q10 |
MX363435B (en) | 2007-03-22 | 2019-03-22 | Berg Llc | Topical formulations having enhanced bioavailability. |
US20110136231A1 (en) | 2008-04-11 | 2011-06-09 | Cytotech Labs, Llc | Methods and use of inducing apoptosis in cancer cells |
BRPI1010576A2 (en) | 2009-05-11 | 2016-03-15 | Berg Biosystems Llc | methods for treating oncological disorders using epimetabolic protractors, multidimensional intracellular molecules or environmental influencers. |
MY163995A (en) | 2010-03-12 | 2017-11-15 | Berg Llc | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
WO2012129072A1 (en) | 2011-03-18 | 2012-09-27 | Particle Dynamics International, Llc | Solid particulate compositions comprising coenzyme q10 |
WO2012138765A1 (en) | 2011-04-04 | 2012-10-11 | Berg Pharma Llc | Methods of treating central nervous system tumors |
US20140239525A1 (en) | 2011-06-17 | 2014-08-28 | Board Of Regents, University Of Texas System | Inhalable pharmaceutical compositions |
EP2983654A4 (en) | 2013-04-08 | 2016-11-30 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
EP3041496B1 (en) | 2013-09-04 | 2020-04-29 | Berg LLC | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
US9138453B2 (en) | 2013-10-14 | 2015-09-22 | Biomarker Pharmaceuticals, Inc. | Nutrient combinations for affecting an aging process |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5742616A (en) * | 1980-08-27 | 1982-03-10 | Furointo Sangyo Kk | Ubiquinone pharmaceutical having improved absorption |
WO2002009685A1 (en) * | 2000-07-28 | 2002-02-07 | Steigerwald Arzneimittelwerk Gmbh | Preparation with vascular protective and anti-oxidative effect and use thereof |
US20030147927A1 (en) * | 2001-11-14 | 2003-08-07 | Khan Mansoor A. | Eutectic-based self-nanoemulsified drug delivery system |
WO2003105607A1 (en) * | 2002-06-12 | 2003-12-24 | Nutralease Ltd. | Nano-sized self-assembled structured liquids |
Family Cites Families (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2263753B1 (en) | 1974-03-12 | 1978-07-21 | Roeck Yannick De | |
JPS5581813U (en) | 1978-11-29 | 1980-06-05 | ||
JPS5581813A (en) | 1978-12-16 | 1980-06-20 | Nisshin Flour Milling Co Ltd | Composition containing coenzyme q10 and its perparation |
IT1206954B (en) | 1979-02-12 | 1989-05-17 | Sigma Tau Ind Farmaceuti | THERAPEUTIC AGENTS BASED ON AN ACIL DERIVATIVE OF CARNITINE FOR THE TREATMENT OF PERIPHERAL VASCULOPATHIES |
JPS5671034A (en) | 1979-11-12 | 1981-06-13 | Japan Tobacco Inc | 4-keto-alpha-cyclocitral and improver of aroma and flavor of tobacco composed thereof |
JPS5770815A (en) | 1980-10-21 | 1982-05-01 | Furointo Sangyo Kk | Absorption improver |
JPS57142911A (en) | 1981-02-28 | 1982-09-03 | Furointo Sangyo Kk | Absorption-improving agent |
JPS6116815Y2 (en) | 1981-03-03 | 1986-05-23 | ||
JPS58180427A (en) | 1982-04-16 | 1983-10-21 | Tetsuya Suzuki | Preparation of substance having hypotensive component |
CH655005A5 (en) | 1983-02-16 | 1986-03-27 | Sigma Tau Ind Farmaceuti | PHARMACEUTICAL COMPOSITION WITH METABOLIC AND ENERGY ACTION USABLE IN CARDIAC AND VASCULAR THERAPY. |
JPS59172417A (en) | 1983-03-23 | 1984-09-29 | Nisshin Kagaku Kk | Soft capsule containing riboflavin butyrate |
JPS59172417U (en) | 1983-05-04 | 1984-11-17 | 北島 信男 | Water pillow that can be cooled by electricity |
US4559222A (en) | 1983-05-04 | 1985-12-17 | Alza Corporation | Matrix composition for transdermal therapeutic system |
JPS6025918A (en) | 1983-07-25 | 1985-02-08 | Ajinomoto Co Inc | Aqueous solution containing fat-soluble drug |
US4687782A (en) | 1984-12-10 | 1987-08-18 | Nutri-Fuels Systems, Inc. | Nutritional composition for enhancing skeletal muscle adaptation to exercise training |
DE3512054A1 (en) | 1985-04-02 | 1986-10-02 | HERMES Fabrik pharmazeutischer Präparate Franz Gradinger Gmbh & Co, 8023 Großhesselohe | PHARMACEUTICAL PREPARATION |
US4824669A (en) * | 1985-04-11 | 1989-04-25 | Board Of Regents, The University Of Texas System | Formulations of coenzyme Q10 for intravenous use |
US5030458A (en) | 1989-11-27 | 1991-07-09 | Shug Austin L | Method for preventing diet-induced carnitine deficiency in domesticated dogs and cats |
WO1988003015A1 (en) | 1986-10-23 | 1988-05-05 | Arval S.P.A. | Cosmetic preparations containing ubidecarenones |
KR900007659B1 (en) | 1987-02-23 | 1990-10-18 | 시세이도 가부시끼가이샤 | Percutaneous absorption promator and dermatologic preparation for external use |
US4871718A (en) | 1987-12-29 | 1989-10-03 | Raymond A. Roncari | Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair |
US5290605A (en) | 1989-06-29 | 1994-03-01 | Niva Shapira | Sun-exposure nutritional supporting composition |
US5532002A (en) | 1989-08-17 | 1996-07-02 | Cortecs Limited | Gelatin pharmaceutical formulations |
US5711950A (en) | 1990-01-12 | 1998-01-27 | Lorenzen; Lee H. | Process for preparing microclustered water |
US6300361B1 (en) | 1990-07-25 | 2001-10-09 | Novartis Ag | Stabilized pharmaceutical compositions comprising acid donors |
US5310578A (en) | 1990-09-17 | 1994-05-10 | Merck Patent Gesellschaft | Deposition of cosmetically functional material onto pigments and fillers |
US5298246A (en) | 1991-01-09 | 1994-03-29 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Stable pharmaceutical composition and method for its production |
US5378461A (en) | 1991-07-12 | 1995-01-03 | Neigut; Stanley J. | Composition for the topical treatment of skin damage |
EP0543417A1 (en) | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotrienols and tocotrienol-like compounds and methods for their use |
US5240961A (en) | 1992-07-02 | 1993-08-31 | Shug Austin L | Method of treating reduced insulin-like growth factor and bone loss associated with aging |
US5756291A (en) | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
US5362753A (en) | 1993-04-19 | 1994-11-08 | Lonza Ltd. | Method of increasing the hatchability of eggs by feeding hens carnitine |
US5431916A (en) | 1993-04-29 | 1995-07-11 | The Procter & Gamble Company | Pharmaceutical compositions and process of manufacture thereof |
US6218436B1 (en) | 1993-06-28 | 2001-04-17 | The Howard Foundation | Pharmaceutically active carotenoids |
DE4327063A1 (en) | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenone particles with modified physicochemical properties |
US6054136A (en) | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
US5438042B1 (en) | 1993-10-08 | 1997-08-26 | Sandoz Nutrition Ltd | Enteral nutritional composition having amino acid profile |
FR2714598B1 (en) | 1993-12-30 | 1996-02-09 | Oreal | Slimming composition with two types of liposomes for topical treatment, its use. |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
DE4410238A1 (en) | 1994-03-25 | 1995-09-28 | Beiersdorf Ag | Skin care products |
CZ293696A3 (en) | 1994-04-07 | 1997-01-15 | Smithkline Beecham Plc | Free base holofantrin for malaria treating and pharmaceutical compositions containing thereof |
US5686491A (en) | 1994-09-14 | 1997-11-11 | Sigma-Tau Pharmaceuticals, Inc. | Infant formula |
US5512691A (en) | 1994-11-07 | 1996-04-30 | Eastman Chemical Company | Process for the production of tocopherol concentrates |
US5670320A (en) | 1994-11-14 | 1997-09-23 | Emory University | Detection of mitochondrial DNA mutation 14459 associated with dystonia and/or Leber's hereditary optic neuropathy |
DE19603402A1 (en) | 1995-02-24 | 1996-08-29 | Basf Ag | Soft gelatin capsules |
US5552167A (en) | 1995-05-05 | 1996-09-03 | Nabisco, Inc. | Rice bran oil antioxidant |
US5716928A (en) | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5626849A (en) | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
US5560928A (en) | 1995-06-23 | 1996-10-01 | Defelice; Stephen L. | Nutritional and/or dietary composition and method of using the same |
DE19537027A1 (en) | 1995-10-05 | 1997-04-10 | Beiersdorf Ag | Skin care product for old skin |
AU724620B2 (en) | 1996-01-16 | 2000-09-28 | Sokol, Ronald J Dr. | Use of antioxidant agents to treat cholestatic liver disease |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US5948443A (en) | 1996-02-23 | 1999-09-07 | Medical Doctor's Research Institute, Inc. | Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
US6056971A (en) | 1996-07-24 | 2000-05-02 | Biosytes Usa, Inc. | Method for enhancing dissolution properties of relatively insoluble dietary supplements and product incorporating same |
KR980008239A (en) | 1996-07-26 | 1998-04-30 | 김충환 | Cyclosporin-containing pharmaceutical composition |
US6579854B1 (en) | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
JP3889481B2 (en) | 1996-08-16 | 2007-03-07 | 株式会社カネカ | Pharmaceutical composition |
US5891469A (en) | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
US5977162A (en) | 1996-09-16 | 1999-11-02 | Seidman; Michael D. | Therapeutic treatment for auditory function |
US5976568A (en) | 1997-02-21 | 1999-11-02 | Medical Doctors' Research Institute, Inc. | Modular system of dietary supplement compositions for optimizing health benefits and methods |
GB9704904D0 (en) | 1997-03-10 | 1997-04-30 | Riley Fletcher Foundation The | Essential oil composition |
PL193414B1 (en) | 1997-03-12 | 2007-02-28 | Abbott Lab | Hydrophilic two-component systems for use in administration of cyclosporine |
DE69826253D1 (en) | 1997-03-20 | 2004-10-21 | Coventry Group Ltd | NUTRITIONAL SUPPLEMENT FOR CARDIOVASCLEAR HEALTH |
US6232346B1 (en) | 1997-03-27 | 2001-05-15 | Michael J. Sole | Composition for improvement of cellular nutrition and mitochondrial energetics |
US6080788A (en) | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
JP3926888B2 (en) | 1997-05-27 | 2007-06-06 | 株式会社カネカ | Cholesterol lowering agent |
AU7826798A (en) | 1997-06-09 | 1998-12-30 | Board Of Regents, The University Of Texas System | Superiority of formulations containing coenzyme q10 in coconut oil |
US6503483B2 (en) | 1997-06-12 | 2003-01-07 | C.S. Bioscience, Inc. | Dental formulation |
US6207137B1 (en) | 1997-06-12 | 2001-03-27 | C.S. Bioscience, Inc. | Dental formulation |
EP0888774A3 (en) * | 1997-06-30 | 1999-11-10 | Soft Gel Technologies, Inc. | Soft gel Coenzyme Q10 formulation |
US5985344A (en) | 1997-09-02 | 1999-11-16 | The Ricex Company | Process for obtaining micronutrient enriched rice bran oil |
JP4761093B2 (en) | 1997-12-10 | 2011-08-31 | シクロスポリン セラポイティクス リミテッド | Pharmaceutical composition comprising omega-3 fatty acid oil |
US6048846A (en) | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
US6503523B2 (en) | 1998-05-07 | 2003-01-07 | Gs Development A.B. | Skin care agents containing combinations of active agents consisting of vitamin a derivatives and UBI- or plastoquinones |
US6063432A (en) | 1998-05-19 | 2000-05-16 | Cooke Pharma | Arginine or lysine containing fruit healthbar formulation |
US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
US6174547B1 (en) | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
US6048886A (en) | 1998-10-05 | 2000-04-11 | Neigut; Stanley | Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin |
US6277431B1 (en) | 1998-10-14 | 2001-08-21 | Redeem, Inc. | Anticholesterolemic edible oil |
US6200550B1 (en) | 1998-12-11 | 2001-03-13 | Q-Pharma, Inc. | Oral care compositions comprising coenzyme Q10 |
US6020383A (en) | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6258380B1 (en) | 1999-03-05 | 2001-07-10 | Banner Pharmacaps, Inc. | Chewable soft capsule |
US6616942B1 (en) | 1999-03-29 | 2003-09-09 | Soft Gel Technologies, Inc. | Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing |
US6368618B1 (en) | 1999-07-01 | 2002-04-09 | The University Of Georgia Research Foundation, Inc. | Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs |
US6562869B1 (en) | 1999-09-23 | 2003-05-13 | Juvenon, Inc. | Nutritional supplement for increased energy and stamina |
WO2001021208A1 (en) | 1999-09-23 | 2001-03-29 | Juvenon Corporation | Nutritional supplement for increased energy and stamina |
US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
US6426362B1 (en) | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
US6455589B1 (en) | 1999-10-28 | 2002-09-24 | The Regents Of The University Of California | Primary N-hydroxylamines |
JP2003513039A (en) | 1999-11-03 | 2003-04-08 | ジュヴェノン インコーポレイテッド | How to treat benign amnesia |
US6716451B1 (en) | 1999-11-30 | 2004-04-06 | Soft Gel Technologies, Inc. | Formulation and delivery method to enhance antioxidant potency of vitamin E |
US6740338B1 (en) | 2000-01-20 | 2004-05-25 | Raj K. Chopra | Reduced form of Cenzyme Q in high bioavailability stable oral dosage form |
US8753675B1 (en) | 2000-01-20 | 2014-06-17 | Raj K. Chopra | Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications |
EP1253903B1 (en) | 2000-01-31 | 2006-05-17 | Engelhard Corporation | Surfactant free topical compositions and method for rapid preparation thereof |
US6664287B2 (en) | 2000-03-15 | 2003-12-16 | Bethesda Pharmaceuticals, Inc. | Antioxidants |
US6365181B1 (en) | 2000-04-20 | 2002-04-02 | Gattefosse Corporation | Thixatropic gelatin carrier composition |
ES2252230T3 (en) | 2000-05-11 | 2006-05-16 | Bristol-Myers Squibb Company | USEFUL TETRAHYDROISOQUINOLINE ANALOGS AS SECRETORS OF GROWTH HORMONE. |
CA2407896A1 (en) | 2000-06-20 | 2001-12-27 | Nutrition Sciences | Medium chain fatty acids applicable as antimicrobial agents |
US6623734B2 (en) | 2000-06-22 | 2003-09-23 | Soft Gel Technologies, Inc. | Super absorption coenzyme Q10 |
US6545184B1 (en) | 2000-08-15 | 2003-04-08 | The Regents Of The University Of California | Practical, cost-effective synthesis of COQ10 |
US6441050B1 (en) | 2000-08-29 | 2002-08-27 | Raj K. Chopra | Palatable oral coenzyme Q liquid |
US6342526B1 (en) | 2000-09-18 | 2002-01-29 | Lonza Ltd. | Method for enhancing or achieving training-induced bradycardia with Carnitine |
US6552004B1 (en) | 2000-10-30 | 2003-04-22 | Universite De Montreal | Delivery system for entrapping charged macromolecules and a method for preparing same |
US6790465B2 (en) | 2000-12-01 | 2004-09-14 | Snore-Fix, Inc. | Composition and method for treating snoring |
US20020098172A1 (en) | 2001-01-24 | 2002-07-25 | Udell Ronald G. | Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing |
US6855733B2 (en) | 2001-01-24 | 2005-02-15 | Soft Gel Technologies, Inc. | Formulation and manufacturing process for coenzyme Q10 soft gel capsules |
US6300377B1 (en) | 2001-02-22 | 2001-10-09 | Raj K. Chopra | Coenzyme Q products exhibiting high dissolution qualities |
US6630170B2 (en) | 2001-04-26 | 2003-10-07 | Board Of Regents The University Of Texas System | Mesoporous compositions and method of preparation |
US6730319B2 (en) | 2001-06-06 | 2004-05-04 | Hoffmann-La Roche Inc. | Pharmaceutical compositions having depressed melting points |
US6506915B1 (en) | 2001-06-14 | 2003-01-14 | Daniel David West | Synthesis of coenzyme Q10 ubiquinone |
US6436431B1 (en) | 2001-07-02 | 2002-08-20 | Diane Wright Hoffpauer | Fortified rice bran food product and method for promoting cardiovascular health |
US20030044474A1 (en) | 2001-08-03 | 2003-03-06 | Shaklee Corporation | High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability |
US6503506B1 (en) | 2001-08-10 | 2003-01-07 | Millenium Biotechnologies, Inc. | Nutrient therapy for immuno-compromised patients |
JP3549197B2 (en) | 2001-08-10 | 2004-08-04 | 日清ファルマ株式会社 | Ubiquinone-containing preparations |
JP2003055204A (en) | 2001-08-21 | 2003-02-26 | Sansho Iyaku Kk | Ubidecarenone composition and capsule comprising the composition as content |
US20030082168A1 (en) | 2001-10-22 | 2003-05-01 | Inna Yegorova | Compositions and methods for facilitating weight loss |
US6806259B2 (en) | 2001-12-21 | 2004-10-19 | Soft Gel Technologies, Inc. | Hyaluronic Acid in soft gel form |
US20030190343A1 (en) | 2002-03-05 | 2003-10-09 | Pfizer Inc. | Palatable pharmaceutical compositions for companion animals |
US8097279B2 (en) | 2002-04-25 | 2012-01-17 | Banner Pharmacaps Inc. | Chewable soft capsule |
JP4226846B2 (en) | 2002-06-07 | 2009-02-18 | キャタレント・ジャパン株式会社 | Soft capsule that can disintegrate in the oral cavity |
US20040001874A1 (en) | 2002-06-24 | 2004-01-01 | Vital Living, Inc. | Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods |
US7815943B2 (en) * | 2002-08-22 | 2010-10-19 | 4Life Research, Lc | Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition |
FR2850275B1 (en) | 2003-01-24 | 2005-04-08 | Scherer Technologies Inc R P | SOFT MACHINE CAPSULES CONTAINING AN ACTIVE ACTIVE SUBSTANCE WITH MASK TASTE |
MXPA05013857A (en) * | 2003-06-25 | 2006-05-17 | Charles Erwin | Chemical combination and method for increasing delivery of coenzyme q 10. |
US20080089877A1 (en) | 2003-08-14 | 2008-04-17 | Udell Ronald G | Super Absorption Coenzyme Q10 |
US8124072B2 (en) | 2003-09-29 | 2012-02-28 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
US7169385B2 (en) | 2003-09-29 | 2007-01-30 | Ronald G. Udell | Solubilized CoQ-10 and carnitine |
EP1670325A1 (en) | 2003-09-29 | 2006-06-21 | Soft Gel Technologies, Inc. | SOLUBILIZED CoQ-10 |
AU2005224245A1 (en) | 2004-03-23 | 2005-09-29 | Kaneka Corporation | Coenzyme Q composition with long-term persistence in blood |
US20080020022A1 (en) | 2006-06-05 | 2008-01-24 | Udell Ronald G | Chewable co-enzyme q-10 capsule |
US8343541B2 (en) | 2007-03-15 | 2013-01-01 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic acid compositions |
JP5770815B2 (en) | 2013-11-01 | 2015-08-26 | 云辰電子開發股▲分▼有限公司 | Wireless monitoring control method and apparatus |
-
2004
- 2004-09-29 EP EP04785186A patent/EP1670325A1/en not_active Withdrawn
- 2004-09-29 WO PCT/US2004/031775 patent/WO2005032278A1/en active Search and Examination
- 2004-09-29 US US10/953,328 patent/US8105583B2/en not_active Expired - Lifetime
- 2004-09-29 AU AU2004277951A patent/AU2004277951B2/en active Active
-
2012
- 2012-01-24 US US13/357,402 patent/US8658161B2/en not_active Expired - Lifetime
-
2014
- 2014-01-27 US US14/165,319 patent/US8932585B2/en not_active Expired - Lifetime
- 2014-12-04 US US14/560,136 patent/US20150306048A1/en not_active Abandoned
-
2016
- 2016-08-05 US US15/229,624 patent/US10314793B2/en not_active Expired - Lifetime
-
2019
- 2019-04-29 US US16/396,983 patent/US20190343778A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5742616A (en) * | 1980-08-27 | 1982-03-10 | Furointo Sangyo Kk | Ubiquinone pharmaceutical having improved absorption |
WO2002009685A1 (en) * | 2000-07-28 | 2002-02-07 | Steigerwald Arzneimittelwerk Gmbh | Preparation with vascular protective and anti-oxidative effect and use thereof |
US20030147927A1 (en) * | 2001-11-14 | 2003-08-07 | Khan Mansoor A. | Eutectic-based self-nanoemulsified drug delivery system |
WO2003105607A1 (en) * | 2002-06-12 | 2003-12-24 | Nutralease Ltd. | Nano-sized self-assembled structured liquids |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Section Ch Week 198216, Derwent World Patents Index; Class A96, AN 1982-31657E, XP002313489 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10166192B2 (en) | 2003-09-29 | 2019-01-01 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
US10314793B2 (en) | 2003-09-29 | 2019-06-11 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
US7713523B2 (en) | 2003-09-29 | 2010-05-11 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 and carnitine |
US8865032B2 (en) | 2003-09-29 | 2014-10-21 | Soft Gel Technologies, Inc. | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene |
US8932584B2 (en) | 2003-09-29 | 2015-01-13 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
US8932585B2 (en) | 2003-09-29 | 2015-01-13 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
US10166193B2 (en) | 2003-09-29 | 2019-01-01 | Soft Gel Technologies, Inc. | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene |
JP2007297395A (en) * | 2006-05-05 | 2007-11-15 | Softgel Formulators Inc | Highly absorbable coenzyme q10 composition and method for producing the same |
WO2007143651A2 (en) * | 2006-06-05 | 2007-12-13 | Soft Gel Technologies, Inc. | Chewable co-enzyme q-10 capsule |
WO2007143651A3 (en) * | 2006-06-05 | 2008-01-24 | Soft Gel Technologies Inc | Chewable co-enzyme q-10 capsule |
WO2008113066A2 (en) * | 2007-03-15 | 2008-09-18 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic compositions |
US9889096B2 (en) * | 2007-03-15 | 2018-02-13 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic acid compositions |
US9345672B2 (en) | 2007-03-15 | 2016-05-24 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic acid compositions |
US20190008783A1 (en) * | 2007-03-15 | 2019-01-10 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic acid compositions |
WO2008113066A3 (en) * | 2007-03-15 | 2009-08-27 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic compositions |
Also Published As
Publication number | Publication date |
---|---|
US20190343778A1 (en) | 2019-11-14 |
US10314793B2 (en) | 2019-06-11 |
US20170119696A1 (en) | 2017-05-04 |
US8105583B2 (en) | 2012-01-31 |
US8658161B2 (en) | 2014-02-25 |
US8932585B2 (en) | 2015-01-13 |
US20150306048A1 (en) | 2015-10-29 |
EP1670325A1 (en) | 2006-06-21 |
US20050069582A1 (en) | 2005-03-31 |
US20140140974A1 (en) | 2014-05-22 |
AU2004277951A1 (en) | 2005-04-14 |
US20120121566A1 (en) | 2012-05-17 |
AU2004277951B2 (en) | 2010-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10314793B2 (en) | Solubilized CoQ-10 | |
US10166193B2 (en) | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene | |
US7713523B2 (en) | Solubilized CoQ-10 and carnitine | |
US20080020022A1 (en) | Chewable co-enzyme q-10 capsule | |
EP2073793A2 (en) | Compositions containing coenzyme q-10 in reduced form and dihydrolipoic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006528309 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 174624 Country of ref document: IL Ref document number: 2004277951 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004785186 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004277951 Country of ref document: AU |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2004785186 Country of ref document: EP |